Development of Liposomal Ciprofloxacin to Treat Lung Infections
about
Current Trends in Development of Liposomes for Targeting Bacterial BiofilmsInhalable Antimicrobials for Treatment of Bacterial Biofilm-Associated Sinusitis in Cystic Fibrosis Patients: Challenges and Drug Delivery Approaches.What's new in the management of adult bronchiectasis?Inhaled Antibiotic Therapy in Chronic Respiratory Diseases.Inhaled Liposomal Ciprofloxacin Protects against a Lethal Infection in a Murine Model of Pneumonic Plague.The long and winding road to inhaled TB therapy: not only the bug's fault.How Much Surface Coating of Hydrophobic Azithromycin Is Sufficient to Prevent Moisture-Induced Decrease in Aerosolisation of Hygroscopic Amorphous Colistin Powder?Whether a novel drug delivery system can overcome the problem of biofilms in respiratory diseases?Inhaled or nebulised ciprofloxacin for the maintenance treatment of bronchiectasis.Lysozyme Associated Liposomal Gentamicin Inhibits Bacterial Biofilm.Tuning Ciprofloxacin Release Profiles from Liposomally Encapsulated Nanocrystalline Drug.Enhancement of lung gene delivery after aerosol: a new strategy using non-viral complexes with antibacterial properties.Targeting microbial biofilms: current and prospective therapeutic strategies.Physico-Chemical Properties, Aerosolization and Dissolution of Co-Spray Dried Azithromycin Particles with L-Leucine for Inhalation.The Rationale and Evidence for Use of Inhaled Antibiotics to Control Pseudomonas aeruginosa Infection in Non-cystic Fibrosis Bronchiectasis.Pulmonary drug delivery system: newer patents.Preparation and characterization of alginate/chitosan formulations for ciprofloxacin-controlled delivery.Surviving nebulization-induced stress: dexamethasone in pH-sensitive archaeosomes.The pharmacological treatment of bronchiectasis.Inhalational Gentamicin Treatment Is Effective Against Pneumonic Plague in a Mouse Model.
P2860
Q26865495-0EDA9CB7-0682-41C5-A819-9FACEEF3C4DEQ28077482-D44564D3-2A6E-4EC2-AE85-2380AD6F9607Q33589288-FDEDF96F-14B6-41A0-9800-3D65F567ACADQ33755342-5DD6EFD2-4494-4CBA-A998-6586B6CEB6E3Q37625356-00AB4163-1044-417A-BB64-B8F87923CFD9Q38782463-75604335-1F51-4C8F-AFAB-3DF39DD577CAQ38859067-8B2A6985-8249-47C4-8ED5-CFC317D21971Q39031123-A7296838-6739-4FE4-86AA-594CCA92107DQ40106308-AD110563-B76F-4FFE-8B9B-FBA89CA63D2AQ40256475-DA44A764-6D43-4DE9-9D57-7F2E8EB9E87DQ41210900-0EC347E4-0814-47E8-B3A3-37064BBDBEE6Q44832157-433ECA5E-0966-4FBF-952F-B085A1AF5992Q47637669-2BE831EE-DF31-41D7-8CCB-B52F5747C4B0Q47646246-BD39F739-0D60-445B-963D-514208BB8425Q47730320-41692941-313E-4E78-AE35-3FB576F227A8Q47783727-3A766EBF-2876-4835-A317-3EB10E2CBEA5Q47987073-CEA7E46A-A026-40E0-8F2D-583871DDA68DQ51227992-EF916862-ED70-4DE3-8782-0EDF3271174EQ51751531-B9115E2F-C8B1-47DD-A885-CF6F7A6250FBQ54217642-CDA828F2-0CD0-4B01-A99D-6A0B3AE90756
P2860
Development of Liposomal Ciprofloxacin to Treat Lung Infections
description
2016 nî lūn-bûn
@nan
2016 թուականին հրատարակուած գիտական յօդուած
@hyw
2016 թվականին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Development of Liposomal Ciprofloxacin to Treat Lung Infections
@ast
Development of Liposomal Ciprofloxacin to Treat Lung Infections
@en
Development of Liposomal Ciprofloxacin to Treat Lung Infections
@nl
type
label
Development of Liposomal Ciprofloxacin to Treat Lung Infections
@ast
Development of Liposomal Ciprofloxacin to Treat Lung Infections
@en
Development of Liposomal Ciprofloxacin to Treat Lung Infections
@nl
prefLabel
Development of Liposomal Ciprofloxacin to Treat Lung Infections
@ast
Development of Liposomal Ciprofloxacin to Treat Lung Infections
@en
Development of Liposomal Ciprofloxacin to Treat Lung Infections
@nl
P2860
P3181
P1433
P1476
Development of Liposomal Ciprofloxacin to Treat Lung Infections
@en
P2093
Igor Gonda
Jim Blanchard
P2860
P3181
P356
10.3390/PHARMACEUTICS8010006
P407
P577
2016-03-01T00:00:00Z